Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 4/20 | 0.49 |
| ▸ | HSPA2 | P54652 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 6/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSB | P07858 | 4/20 | 0.47 |
| ▸ | CTSK | P43235 | 5/20 | 0.41 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.41 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.39 |
| ▸ | CTSV | O60911 | 2/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609373 | 0.90 | HSPA5 (0.49) | HSPA5HSPA2CTSLCTSSCTSB | |
| SCHEMBL7813672 | 0.86 | HSPA5 (0.49) | HSPA5HSPA2CTSLCTSSCTSB | |
| SCHEMBL7470442 | 0.85 | CTSL (0.47) | CTSLCTSSCTSBCTSKPRMT5 | |
| SCHEMBL7806106 | 0.85 | HSPA5 (0.49) | HSPA5HSPA2CTSLCTSSCTSB | |
| SCHEMBL6623377 | 0.83 | CTSL (0.47) | CTSLCTSSCTSBCTSKPRMT5 | |
| SCHEMBL6929841 | 0.82 | REN (0.45) | CTSLCTSSCTSBCTSK | |
| SCHEMBL7473368 | 0.82 | CTSK (0.52) | CTSLCTSSCTSBCTSK | |
| SCHEMBL7612563 | 0.81 | CTSL (0.37) | HSPA5HSPA2CTSLCTSSCTSB | |
| Trifluoroacetic Acid SCHEMBL7611852 | 0.78 | CTSL (0.45) | CTSLCTSSCTSBCTSKPRMT5 | |
| SCHEMBL7463889 | 0.77 | CTSL (0.49) | CTSLCTSSCTSBCTSKCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1067894-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6518267-B1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-02-11 | — | — | US | disclosed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1067894-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999059526-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | HSPA5 866/4885HSPA2 1923/4885CTSL 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.